Biller Jonathan's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Oct 3, 2025
- Accession no.
- 0000875320-25-000224
- Filed
- Oct 3, 2025
- Trade date
- Oct 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $280.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biller JonathanCIK 0001744749 | Officer (EVP and Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 1, 2025 | Common Stock | FTax withholdingDisposed | −1,259 | $400.00 | −$503,600 | 16,347 | Direct | |
| Oct 2, 2025 | Common Stock | SSaleDisposed | −694 | $404.21 | −$280,521.74 | 15,653 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.